CN101014597A - 可用作rock和其他蛋白激酶抑制剂的吖吲哚 - Google Patents

可用作rock和其他蛋白激酶抑制剂的吖吲哚 Download PDF

Info

Publication number
CN101014597A
CN101014597A CNA2005800164388A CN200580016438A CN101014597A CN 101014597 A CN101014597 A CN 101014597A CN A2005800164388 A CNA2005800164388 A CN A2005800164388A CN 200580016438 A CN200580016438 A CN 200580016438A CN 101014597 A CN101014597 A CN 101014597A
Authority
CN
China
Prior art keywords
disease
compound according
chr
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800164388A
Other languages
English (en)
Chinese (zh)
Inventor
J·格林
A·米勒
J－M·吉梅那兹
C·玛海夫卡
曹景蓉
J·J·科特
U·K·班达拉格
高淮
S·南萨库玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101014597A publication Critical patent/CN101014597A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
CNA2005800164388A 2004-04-02 2005-04-04 可用作rock和其他蛋白激酶抑制剂的吖吲哚 Pending CN101014597A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55904104P 2004-04-02 2004-04-02
US60/559,041 2004-04-02

Publications (1)

Publication Number Publication Date
CN101014597A true CN101014597A (zh) 2007-08-08

Family

ID=34983212

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800164388A Pending CN101014597A (zh) 2004-04-02 2005-04-04 可用作rock和其他蛋白激酶抑制剂的吖吲哚

Country Status (14)

Country Link
US (1) US7514448B2 (enExample)
EP (1) EP1756108A2 (enExample)
JP (1) JP5019612B2 (enExample)
KR (1) KR20070002081A (enExample)
CN (1) CN101014597A (enExample)
AR (1) AR049333A1 (enExample)
AU (1) AU2005236002A1 (enExample)
CA (1) CA2561724A1 (enExample)
IL (1) IL178414A0 (enExample)
MX (1) MXPA06011328A (enExample)
NO (1) NO20064976L (enExample)
RU (1) RU2006138621A (enExample)
TW (1) TW200604168A (enExample)
WO (1) WO2005103050A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666509A (zh) * 2009-12-14 2012-09-12 默克专利有限公司 用于治疗诸如癌症这样的疾病的噻唑衍生物
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
WO2018108156A1 (zh) * 2016-12-16 2018-06-21 成都先导药物开发有限公司 Rock抑制剂及其应用
WO2018210314A1 (zh) * 2017-05-19 2018-11-22 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN115916776A (zh) * 2020-06-09 2023-04-04 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂及其使用方法
CN116768881A (zh) * 2023-06-30 2023-09-19 郑州大学 4-(3-吲哚基)-1,3-噻唑类化合物及其制备方法和应用

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
EP1708697A4 (en) * 2004-01-30 2007-11-28 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP2332940B1 (en) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
MXPA06014415A (es) 2004-06-24 2007-02-19 Shionogi & Co Compuestos de sulfonamida.
WO2006004984A1 (en) * 2004-06-30 2006-01-12 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
MX2007000092A (es) * 2004-06-30 2007-03-07 Vertex Pharma Azaindoles utiles como inhibidores de proteinas cinasas.
AU2005272815A1 (en) * 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of ATP-utilizing enzymes
CN101098872B (zh) * 2004-11-22 2012-09-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
EP1864971A4 (en) * 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
NZ564065A (en) * 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
BRPI0613591A2 (pt) 2005-07-08 2011-01-18 Novo Nordisk As ativadores de dicicloalquil uréia glicocinase
EP2377856A1 (en) 2005-07-14 2011-10-19 Novo Nordisk A/S Urea glucokinase activators
WO2007026920A2 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1968568A4 (en) * 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
CN102532134A (zh) 2006-01-17 2012-07-04 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
WO2007082808A2 (en) * 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-hsd1 inhibitors
EP1989205B1 (en) * 2006-01-23 2012-06-13 Vertex Pharmceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
US20100004277A1 (en) * 2006-01-26 2010-01-07 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
CA2648250A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US7829590B2 (en) 2006-04-13 2010-11-09 Guy Brenchley Thiophene-carboxamides useful as inhibitors of protein kinases
AU2007267986A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009538305A (ja) * 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
FR2907120B1 (fr) 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
GB0702259D0 (en) * 2007-02-06 2007-03-14 Eisai London Res Lab Ltd 7-azaindole derivatives
WO2008112297A2 (en) * 2007-03-13 2008-09-18 Yale University Methods of treating cancer by interfering with igf-i receptor signaling
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JP5657252B2 (ja) 2007-08-29 2015-01-21 千寿製薬株式会社 角膜内皮細胞接着促進剤
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
EP2303277A4 (en) * 2008-06-26 2011-08-17 Glaxosmithkline Llc HAMMER OF ACT ACTIVITY
WO2009158374A2 (en) * 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibitors of akt activity
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
TW201006832A (en) * 2008-07-15 2010-02-16 Novartis Ag Organic compounds
JP2011529066A (ja) * 2008-07-23 2011-12-01 バーテックス ファーマシューティカルズ インコーポレイテッド 三環式ピラゾロピリジンキナーゼ阻害剤
KR20110039563A (ko) 2008-07-23 2011-04-19 버텍스 파마슈티칼스 인코포레이티드 피라졸로피리딘 키나제 억제제
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2321318A1 (en) * 2008-07-23 2011-05-18 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
EP2403860B1 (en) * 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
KR101903354B1 (ko) 2009-06-17 2018-10-04 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
MX2012005284A (es) 2009-11-06 2012-06-28 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello.
WO2011094290A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
JP5769733B2 (ja) 2010-01-27 2015-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジンキナーゼ阻害剤
MX2012008641A (es) 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopirazinas.
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8877794B2 (en) * 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2651940A1 (en) 2010-12-16 2013-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
DE102011083283A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Heteroalkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Heteroalkylamidothiazolen
LT2788472T (lt) 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6225178B2 (ja) * 2012-05-31 2017-11-01 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体
CA2878054C (en) 2012-06-29 2018-09-11 Pfizer Inc. Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014177699A1 (en) * 2013-05-03 2014-11-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
WO2015016371A1 (ja) 2013-07-30 2015-02-05 京都府公立大学法人 角膜内皮細胞マーカー
ES2847755T3 (es) 2013-10-31 2021-08-03 Kyoto Prefectural Public Univ Corp Fármaco terapéutico que comprende un inhibidor de la señal de TGF-beta para enfermedades relacionadas con la muerte celular del retículo endoplásmico en el endotelio corneal
ES2684755T3 (es) 2013-11-13 2018-10-04 Vertex Pharmaceuticals Incorporated Métodos para preparar inhibidores de la replicación de virus de la gripe
DK3068776T3 (da) 2013-11-13 2019-07-29 Vertex Pharma Inhibitorer af replikation af influenzavira
MX2016006915A (es) 2013-11-27 2017-01-23 Kyoto Prefectural Public Univ Corp Aplicacion de laminina a cultivo de celulas endoteliales de la cornea.
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
AU2015215582B2 (en) 2014-02-04 2016-10-13 Taiho Pharmaceutical Co., Ltd. Azaindole derivative
AU2015315177A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
ES2947826T3 (es) 2016-02-15 2023-08-21 Kyoto Prefectural Public Univ Corp Célula endotelial corneal funcional humana y aplicación de la misma
ES2841951T3 (es) * 2018-04-17 2021-07-12 Univ Masarykova Propanamidas sustituidas como inhibidores de nucleasas
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US20210207088A1 (en) 2018-08-31 2021-07-08 The Doshisha Composition and method for preserving or culturing ocular cells
KR102797964B1 (ko) 2018-10-02 2025-04-22 학교법인 도시샤 각막 내피 세포를 보존하기 위한 방법 및 용기
SG11202104404XA (en) * 2018-11-16 2021-05-28 California Inst Of Techn Erk inhibitors and uses thereof
CN114040760B (zh) 2018-12-31 2025-05-09 拜欧米富士恩公司 Menin-mll相互作用的不可逆抑制剂
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
WO2021064141A1 (en) * 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN115427551A (zh) 2020-02-27 2022-12-02 京都府公立大学法人 人功能性角膜内皮细胞及其应用
MX2022015525A (es) 2020-06-08 2023-03-23 Vtv Therapeutics Llc Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos.
CA3216719A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
US12251385B2 (en) 2021-08-11 2025-03-18 Biomea Fusion, Inc. Covalent inhibitors of menin-MLL interaction for diabetes mellitus
WO2023022912A1 (en) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
KR20240110954A (ko) 2021-11-11 2024-07-16 학교법인 도시샤 각막 내피 세포의 냉동보존 제제 및 상기 냉동보존 제제를 생산하기 위한 방법
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
CA2479205A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
JP4787150B2 (ja) * 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｊｎｋ阻害剤
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666509A (zh) * 2009-12-14 2012-09-12 默克专利有限公司 用于治疗诸如癌症这样的疾病的噻唑衍生物
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
WO2018108156A1 (zh) * 2016-12-16 2018-06-21 成都先导药物开发有限公司 Rock抑制剂及其应用
CN108203433A (zh) * 2016-12-16 2018-06-26 成都先导药物开发有限公司 一种rock抑制剂及其应用
WO2018210314A1 (zh) * 2017-05-19 2018-11-22 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN110869369A (zh) * 2017-05-19 2020-03-06 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
US11292787B2 (en) 2017-05-19 2022-04-05 Xiamen University Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof
CN110869369B (zh) * 2017-05-19 2022-06-28 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN115916776A (zh) * 2020-06-09 2023-04-04 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂及其使用方法
CN116768881A (zh) * 2023-06-30 2023-09-19 郑州大学 4-(3-吲哚基)-1,3-噻唑类化合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2005103050A2 (en) 2005-11-03
US20060003968A1 (en) 2006-01-05
WO2005103050A3 (en) 2006-10-05
TW200604168A (en) 2006-02-01
AR049333A1 (es) 2006-07-19
EP1756108A2 (en) 2007-02-28
NO20064976L (no) 2006-10-31
IL178414A0 (en) 2007-02-11
RU2006138621A (ru) 2008-05-10
AU2005236002A1 (en) 2005-11-03
MXPA06011328A (es) 2006-12-15
KR20070002081A (ko) 2007-01-04
JP2007531740A (ja) 2007-11-08
JP5019612B2 (ja) 2012-09-05
US7514448B2 (en) 2009-04-07
CA2561724A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
CN101014597A (zh) 可用作rock和其他蛋白激酶抑制剂的吖吲哚
EP1558607B1 (en) Compositions useful as inhibitors of rock and other protein kinases
JP4817661B2 (ja) プロテインキナーゼインヒビターとしてのトリアゾロピリダジン
EP1485381B1 (en) Azolylaminoazine as inhibitors of protein kinases
US7531556B2 (en) Compositions useful as inhibitors of rock and other protein kinases
EP1485376B1 (en) Compositions useful as inhibitors of protein kinases
EP1485380B1 (en) Azolylaminoazines as inhibitors of protein kinases
JP5042888B2 (ja) Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
US20110021559A1 (en) Aminopyridines useful as inhibitors of protein kinases
WO2003077921A1 (en) Azinylaminoazoles as inhibitors of protein kinases
HK1106512A (en) Azaindoles useful as inhibitors of rock and other protein kinases
HK1087700B (en) Triazolopyridazines as protein kinases inhibitors
HK1109567A (en) Triazoles useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1106512

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070808

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1106512

Country of ref document: HK